Search by Drug Name or NDC
NDC 00006-0568-40 ZOLINZA 100 mg/1 Details
ZOLINZA 100 mg/1
ZOLINZA is a ORAL CAPSULE in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Merck Sharp & Dohme LLC. The primary component is VORINOSTAT.
MedlinePlus Drug Summary
Vorinostat is used to treat cutaneous T-cell lymphoma (CTCL, a type of cancer) in people whose disease has not improved, has gotten worse, or has come back after taking other medications. Vorinostat is in a class of medications called histone deacetylase (HDAC) inhibitors. It works by killing or stopping the growth of cancer cells.
Related Packages: 00006-0568-40Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Vorinostat
Product Information
| NDC | 00006-0568 |
|---|---|
| Product ID | 0006-0568_255c6d3a-625e-43a7-ae67-ba5053f6e03f |
| Associated GPIs | 21531575000120 |
| GCN Sequence Number | 061557 |
| GCN Sequence Number Description | vorinostat CAPSULE 100 MG ORAL |
| HIC3 | V3A |
| HIC3 Description | ANTINEOPLAST,HISTONE DEACETYLASE (HDAC) INHIBITORS |
| GCN | 97345 |
| HICL Sequence Number | 034070 |
| HICL Sequence Number Description | VORINOSTAT |
| Brand/Generic | Brand |
| Proprietary Name | ZOLINZA |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | vorinostat |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | CAPSULE |
| Route | ORAL |
| Active Ingredient Strength | 100 |
| Active Ingredient Units | mg/1 |
| Substance Name | VORINOSTAT |
| Labeler Name | Merck Sharp & Dohme LLC |
| Pharmaceutical Class | Histone Deacetylase Inhibitor [EPC], Histone Deacetylase Inhibitors [MoA] |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA021991 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 00006-0568-40 (00006056840)
| NDC Package Code | 0006-0568-40 |
|---|---|
| Billing NDC | 00006056840 |
| Package | 120 CAPSULE in 1 BOTTLE (0006-0568-40) |
| Marketing Start Date | 2006-10-06 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |